Clinical Trial Update: Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema [Phase 4]

View source ↗

Summary

Phase 4 multicenter trial evaluating aflibercept (EYLEA) treatment extended as a second-line regimen for diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Diabetic Macular Edema (DME) | Phase 4 | Status: COMPLETED